Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-02-05 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F, often including press releases or other announcements. The document references an attached press release dated February 1, 2016, but does not contain detailed financial statements or substantive financial data itself. The document length is short (1499 characters), and it primarily serves as a regulatory filing to report the press release. According to the rules, such filings that are announcements or reports of other documents without substantive financial data should be classified as Regulatory Filings (RNS).
2016-02-05 English
Galapagos receives transparency notification from Wellington Management Group LLP
Major Shareholding Notification Classification · 99% confidence The document is a 'transparency notification' received by Galapagos NV regarding a change in major shareholding percentage (falling below the 5% threshold) by Wellington Management Group LLP, citing Belgian transparency legislation. This directly relates to changes in significant share ownership levels. According to the definitions, 'Major Shareholding Notification' (Code: MRQ) covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The document is short and serves as an announcement of this regulatory event, fitting the MRQ category better than a general RNS, as MRQ is more specific to ownership changes.
2016-02-02 English
Galapagos receives transparency notification from Wellington Management Group LLP
Major Shareholding Notification Classification · 99% confidence The document is a press release dated February 1, 2016, titled "Galapagos ontvangt transparantieverklaring van Wellington Management Group LLP" (Galapagos receives transparency declaration from Wellington Management Group LLP). The core content explicitly states that Galapagos received a 'kennisgeving van belangrijke deelneming' (notification of significant shareholding) from Wellington Management Group LLP, indicating that their stake dropped below the 5% threshold following a capital increase. This directly relates to changes in significant share ownership, which corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a press release format, the subject matter is the notification itself, not just an announcement of a report (RPA/RNS).
2016-02-02 English
Wellington TP Final_NL.pdf
Major Shareholding Notification Classification · 98% confidence The document is a press release dated February 1, 2016, titled "Galapagos ontvangt transparantieverklaring van Wellington Management Group LLP" (Galapagos receives transparency declaration from Wellington Management Group LLP). The core content explicitly states that Galapagos received a 'kennisgeving van belangrijke deelneming' (notification of significant shareholding) from Wellington Management Group LLP, indicating that their stake dropped below the 5% threshold following a capital increase. This directly relates to changes in significant share ownership, which corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a press release format, the subject matter is the notification itself, not just an announcement of a report (RPA/RNS).
2016-02-01 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F, often including press releases or other announcements. The document references an attached press release dated January 26, 2016, but does not contain detailed financial statements or substantive financial data itself. The document length is short (1498 characters), and it primarily serves as a regulatory filing to report the press release. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), but rather a Regulatory Filing (RNS) as a general SEC filing of material information by a foreign issuer.
2016-01-27 English
Galapagos reports results with GLPG1205 in ulcerative colitis
Earnings Release Classification · 95% confidence The document is a press release dated January 26, 2016, announcing the results of a clinical trial (ORIGIN Phase 2a study with GLPG1205 for ulcerative colitis) and the subsequent decision to stop development for that indication. It highlights key findings (safety confirmed, efficacy endpoint not met) and provides company background and contact information. This format—a concise announcement of period-specific operational or clinical results, often including forward-looking statements—is characteristic of an Earnings Release (ER) or a general operational update. Since it is specifically reporting on clinical trial results and a development decision, it functions as a key operational update, which aligns best with the 'Earnings Release' category (ER) which often encompasses major operational milestones outside of standard quarterly financial reporting, or potentially a Regulatory Filing (RNS) if it were purely a mandatory disclosure. Given the structure and content focusing on results and future plans, ER is the most appropriate fit among the provided options for a major operational/clinical result announcement. Q1 2016
2016-01-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.